Locations

Our expertise lies in the research of therapeutic and diagnostic innovations for diseases that are currently untreatable or insufficiently treatable. In preclinical research, we use state-of-the-art technologies, such as various MultiOMICs methods, to develop therapeutic approaches and diagnostic biomarkers. In addition, we develop novel experimental systems and disease models to characterize target molecules ("targets") and their modulators (drugs) in vitro, ex vivo and in vivo. Our expertise in pharmaceutical chemistry and technology enables us to optimize new active ingredients as well as their dosage form. In the area of clinical research, our core expertise lies in the planning (study design) and quality-assured execution of clinical studies, as well as in the early clinical development of drug candidates in the in-house Phase I station. An in-house biomaterial bank enables basic scientific analysis for the further characterization of diseases in our indication focus immune-mediated diseases and pain.

Expertise:

• High- and super-resolution microscopy techniques
• Neuroinflammation and degenerative diseases
• iPSC-based 2D- and 3D disease models

Technologies:

• innovative super-resolution microscopy
• automation of microscopy techniques
• innovative image analysis algorithms
• Generation of human iPSC models systems derived from patient samples or using genome editing
• Compound screening using complex iPSC models
• various preclinical models
• Phase I Unit

Our expertise lies in high-throughput drug discovery using high-quality compound and repurposing libraries (in silico and in vitro screening), which enables us to identify pharmacologically active compounds. A comprehensive portfolio of phenotypic and biochemical assays as well as in vitro models based on induced pluripotent stem cells are used to investigate the mechanisms of action. We are also developing workflows to ensure the analysis of drug discovery data and the highest standards of FAIR data management, as well as algorithms and AI tools for the statistical analysis of patient cohorts in different medical indications, thus covering the broad field of »medical data science«.

Expertise:

High throughput drug discovery (in silico, in vitro "screening" and drug repurposing) as well as a broad range of services in the field of "Medical Data Science".

Technologies:

• Comprehensive portfolio of phenotypic and biochemical assays
• in vitro models based on induced pluripotent stem cells
• "Medical Data Science" (development of workflows, algorithms and dashboards, cohort analysis, FAIR data management, Fraunhofer Edge Cloud Health)

We use innovative high- and super-resolution microscopy techniques to visualize sub-cellular structures on the nanoscale. The automation of these techniques and innovative image analysis algorithms allow us to investigate the influence of pharmacologically active substances on the nanostructure of (living) cells with high throughput. In various preclinical models, these substances are examined for their in vivo efficacy within the central nervous system. A modern phase I unit as well as an excellent interdisciplinary team guarantees translation into the clinic and completes our portfolio in the research on new drug candidates for neuroinflammation.

Expertise:

High- and super-resolution microscopy techniques; neuroinflammation and degenerative diseases.

Technologies:

• innovative super-resolution microscopy
• automation of microscopy techniques
• innovative image analysis algorithms
• various preclinical models
• Phase I Unit

Our expertise lies in the research, validation and testing of new diagnostic and therapeutic approaches of allergic and immunological mast cell-mediated inflammatory diseases of the skin. One focus isthe development of a platform of preclinical and prehuman models for the exploration of novel therapies. This includes the identification, characterization and validation of novel therapeutic approaches for subsequent preclinical testing, preclinical research of novel therapeutic approaches to the translation of these approaches into the clinic. Emphasis is placed on the development of a screening program for new biomarkers and predictors, the identification of previously unknown autoallergens, and the development of detection methods for IgE autoantibodies.

Expertise:

Dermatology, allergology, immunological mast cell-mediated inflammatory diseases of the skin.

Research Focus:

• Preclinical human models for the development of new therapeutic approaches
• Screening program for new biomarkers and predictors, identification of previously unknown autoallergens and development of detection methods for IgE autoantibodies

We are engaged in the development of interventions to combat the outbreak of new and the spread of existing infectious diseases. In addition, we aim to improve the therapy of infections and their immunological sequelae. We use our expertise to develop and test new multi-parameter diagnostics, novel antiviral and immunomodulatory therapeutics, and active and passive vaccines. We also focus on the development of new devices, which include both technical solutions to interrupt infection pathways and new "point-of-need" devices for diagnostics. In this context, the use of "Data Science", a topic spanning all fields, is of central importance for our research.

Expertise: 

Developing interventions to address the outbreak of new and spread of existing infectious diseases.

Research Focus:

• Development of new multi-parameter diagnostics, new antiviral and immunomodulatory therapeutics, and active and passive vaccines. 
• Development of new devices to disrupt infectious pathways and new "point-of-need" devices for diagnostics.

The Fraunhofer ITMP IIP site in Penzberg/Munich focuses on the development of interventions to combat the outbreak of new and the spread of existing infectious diseases globally.

The equipment funded by REACT ensures that the laboratory infrastructure can act quickly for various projects within infection and pandemic research. The funding contributes to the rapid development of the institute and the individual departments. The equipment acquired is at the state of the art.